分组1 - Adma Biologics reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share, but showing an increase from $0.08 per share a year ago, resulting in an earnings surprise of -12.50% [1] - The company posted revenues of $114.8 million for the quarter ended March 2025, which was 3.61% below the Zacks Consensus Estimate, compared to $81.88 million in the same quarter last year [2] - Adma Biologics has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has increased approximately 34.8% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $121.1 million, and for the current fiscal year, it is $0.71 on revenues of $495.8 million [7] - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

What's Next for B&G Foods? While B&G Foods has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? B&G Foods (BGS) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -71.43%. A quarter ago, it was expected that this foo ...

One Stop Systems, Inc. (OSS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -75%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced a loss of $0.12, delivering a surprise of -1,300%.Over the last four quarters, the company has n ...

Bloomin' Brands (BLMN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.51%. A quarter ago, it was expected that this owner of Outback Steakhouse and other casual dining spots would post earnings of $0.38 per share when it actually produced earnings of $0.38, delivering no surprise. ...

Forge Global Holdings, Inc. (FRGE) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $1.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.73%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.20, delivering a surprise of 11.11%.Over the last four quarters, the company h ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. What's Next for Apellis Pharmaceuticals? While Apellis Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measu ...

MarketAxess (MKTX) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.75%. A quarter ago, it was expected that this operator of bond trading platforms would post earnings of $1.70 per share when it actually produced earnings of $1.73, delivering a surprise of 1.76%. Over the last four ...

Turning Point Brands (TPB) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 21.33%. A quarter ago, it was expected that this company would post earnings of $0.57 per share when it actually produced earnings of $0.53, delivering a surprise of -7.02%. Over the last four quarters, the co ...

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.35%. A quarter ago, it was expected that this company would post earnings of $0.15 per share when it actually produced earnings of $0.14, delivering a surprise of -6.67%.Over the last four quar ...

Group 1: Earnings Performance - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $332.97 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.08%, compared to year-ago revenues of $300.44 million [2] - Over the last four quarters, LifeStance Health has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - LifeStance Health shares have declined approximately 11.1% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $351.71 million, and -$0.10 on revenues of $1.42 billion for the current fiscal year [7] Group 3: Industry Context - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The favorable estimate revisions trend for LifeStance Health has resulted in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]